Literature DB >> 6811216

Effects of vasodilators on hypoxic pulmonary vasoconstriction in normal man.

R Naeije, C Mélot, P Mols, R Hallemans.   

Abstract

A reduction of arterial PO2 is generally observed when vasodilators are given to patients with cardiac or pulmonary disease. This has been attributed to a release of preexisting hypoxic pulmonary vasoconstriction (HPV). We investigated the effects of hemodynamics and blood gases of IV nitroglycerin, IV nitroprusside and sublingual nifedipine, at dosages currently used in clinical practice, in 23 healthy volunteers at normoxic conditions (fraction of inspired O2, FIO2 0.21) and at acute inspiratory hypoxia (FIO2 0.125 during 10 min). Breathing FIO2 0.125 elicited pulmonary vasoconstriction in all the subjects. At FIO2 0.21, nitroglycerin reduced preload, nifedipine reduced afterload, nitroprusside had balanced effects, but none of the drugs induced pulmonary vasodilation and only nitroglycerin deteriorated arterial oxygenation. At FIO2 0.125, nitroglycerin did not at all affect the pulmonary pressor response, while both nitroprusside and nifedipine decreased it. An inhibition of HPV was obtained with certainty in only one subject who received nitroprusside. In all the subjects in whom HPV was partially inhibited by vasodilator administration, the alveolar-arterial PO2 gradients remained significantly lowered, suggesting that the pulmonary vascular tone adaptation to alveolar hypoxia still was effective in improving ventilation/perfusion relationships. The role of impaired HPV in the reduction of arterial PO2 in patients under vasodilator therapy may have to be reevaluated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811216     DOI: 10.1378/chest.82.4.404

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

1.  Effect of diltiazem on hypoxic pulmonary vasoconstriction in dogs.

Authors:  T Okutomi; C Wakabayashi; K Ikeda
Journal:  J Anesth       Date:  1989-09-01       Impact factor: 2.078

Review 2.  Physiology of the pulmonary circulation and the right heart.

Authors:  Robert Naeije
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

5.  Effects of captopril on pulmonary haemodynamics.

Authors:  C Richard; J L Ricome; A Rimailho; M Conrad; P Auzépy
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 6.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 7.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

8.  Effect of nifedipine on arterial hypoxaemia occurring after methacholine challenge in asthma.

Authors:  E Ballester; J Roca; R Rodriguez-Roisin; A Agusti-Vidal
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

9.  Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; M Van Kuyk; C Melot; P Lejeune; H Ham; F Vertongen; R Naeije
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.